S152 Poster presentations age and symptoms of PSC were related to impairment of by the cumulative duration of steroid therapy (median: 7.1 HRQoL scores, but gen-der, ERC score or comorbidity with months; Q1-Q3: 4.9 12.5), but was negatively correlated with IBD did not have a significant impact on them. The total 15D the evolution of CRP (coefficient of the equation of regression scores between PSC patients (mean 0.934) and the general (e) = 0.16; p < 0.0001) and orosomucoid (e = 0.60; p < 0.0001) population (mean 0.939) did not differ significantly but the during follow-up. dimensions of elimination (p < 0.001), depression (p = 0.003), Conclusions: CD children with uncontrolled inflammatory distress (p = 0.003) and vitality (p = 0.005) were significantly status have a lower growth velocity and a higher risk for growth lower in PSC. In the newly diagnosed, no significant changes failure, regardless of cumulative duration of steroid therapy. were observed in the 15D scores in a mean 1.58 years’ The inflammatory status should be kept normal as much as follow-up. The 15D scores of age-, gender- and IBD activity possible in paediatric-onset CD patients in order to optimize matched IBD patients were lower than those of the PSC patients their growth pattern.

(0.876 versus 0.914, p = 0.04). Downloaded from https://academic.oup.com/ecco-jcc/article/8/Supplement_1/S152/367807 by guest on 29 September 2021 Conclusions: HRQoL of PSC patients was mostly comparable to P216 that of the general population but special attention should be Fecal calprotectin and lactoferrin as predictors of paid to the patients’ psychological well-being. No significant relapse in patients with quiescent ulcerative colitis during HRQoL changes were observed in the mean 1.58 years’ maintenance therapy follow-up after diagnosis of PSC. Newly diagnosed PSC patients T. Yamamoto*, M. Shiraki, S. Umegae, K. Matsumoto. Yokkaichi have better HRQoL than do newly diagnosed IBD patients, Social Insurance Hospital, Inflammatory Bowel Disease Centre, probably because of more intensive follow-up and a different Yokkaichi, Japan spectrum of symptoms. Background: Predictive markers for relapse in patients with Reference(s) ulcerative colitis (UC) on mesalazine maintenance therapy have [1] Haapam¨aki J, Roine RP, Sintonen H, et al., (2010), Health- not been fully determined. Levels of fecal calprotectin and related quality of life in inflammatory bowel disease lactoferrin have a proportional correlation to the degree of measured with the generic 15D instrument. Quality of Life inflammation of the intestinal mucosa. Fecal lactoferrin and Research. lactoferrin may have a role in monitoring disease activity [2] Ponsioen CY, Reitsma JB, Boberg KM, et al., (2010), in patients with IBD. This prospective study was to evaluate Validation of a cholangiographic prognostic model in the significance of fecal calprotectin and lactoferrin for the primary sclerosing cholangitis. Endoscopy. prediction of UC relapse. Methods: Eighty UC patients in remission for 3 months P215 on mesalazine as maintenance therapy were included. At Growth pattern and growth failure in paediatric entry, stool samples were collected for the measurement of Crohn’s disease are related to inflammatory status but not calprotectin and lactoferrin. All patients were followed up to duration of steroid therapy for the following 12 months. To identify predictive factors D. Ley1 *, H. B´ehal2, C. Gower-Rousseau3,4, A. Duhamel2, for relapse, time-dependent analyses using the Kaplan Meier M. Fumery5, F. Vasseur4, L. Michaud1, I. Rousseau4, G. Savoye6, graphs and Cox’s proportional hazard model were applied. D. Turck1. 1University and Hospital, Paediatric, Lille, France, Results: During the 12-month, 21 patients relapsed. Mean 2University and Hospital, Biostatistics EA 2694, Lille, France, calprotectin and lactoferrin levels were significantly higher in 3Health, Epidemiology, Lille, France, 4University and Hospital, patients with relapse than those in remission (calprotectin: Epidemiology, Lille, France, 5University and Hospital, 173.7 vs 135.5 mg/g, P = 0.02 and lactoferrin: 165.1 vs Gastroenterology, Amiens, France, 6University and Hospital, 130.7 mg/g, P = 0.03). A cutoff value of 170 mg/g for calprotectin Gastroenterology, Rouen, France had a sensitivity of 76% and a specificity of 76% to predict relapse, while a cutoff value of 140 mg/g for lactoferrin Background: Growth failure is the main complication of had a sensitivity of 67% and a specificity of 68%. In a paediatric-onset Crohn’s disease (CD). The respective role of multivariate analysis, calprotectin (170 mg/g) was a predictor disease activity and steroid therapy in growth faltering is still of relapse (hazard ratio, 7.23; P = 0.002). None of the following a matter of debate. The aim of the present study was to parameters were significantly associated with relapse: age, investigate whether the growth pattern of children with CD was gender, duration of UC, number of UC episode, severity of the correlated with the evolution of inflammatory status during the previous episode, extent of UC, extraintestinal manifestation, disease course, whatever the cumulative duration of steroid and lactoferrin level. therapy. Conclusions: This study showed that both fecal calprotectin Methods: 107 patients (63 boys and 44 girls) with a diagnosis and lactoferrin levels were very significantly increased in of CD made at less than 17 years of age, followed in the same patients with UC even during remission as compared with unit during more than years and for whom more than 2 height healthy controls. Further, fecal calprotectin level 170 mg/g measures were available during follow-up, were identified was associated with a clinical relapse. Fecal calprotectin level between 1998 and 2012. Height, C-reactive protein (CRP), appeared to be a significant predictor of relapse in patients orosomucoid and information on steroid therapy (including date with quiescent UC on mesalamine as maintenance therapy. of prescription and daily dose) were collected at each visit. Growth velocity was compared to the evolution of inflammatory P217 status during follow-up in a longitudinal multivariate analysis Family functioning and health-related quality of life in using a mixed model. children with inflammatory bowel disease Results: Median age at CD diagnosis was 11.7 years (Q1- L. Caes1 *, C.T. Chambers1,2,3, A. Otley2. 1IWK Health Q3: 9.8 13.5). Growth failure (Height/Age Z-score < 2) was Centre, Centre for Pediatric Pain Research, Halifax, Canada, present in seven patients (8%) at diagnosis and in five (5%) 2Dalhousie University, Department of Pediatrics, Halifax, at maximal follow-up (median: 4.9 years; Q1-Q3: 3.8 6.4). Canada, 3Dalhousie University, Department of Psychology and Among the 75 patients who had achieved their growth at Neuroscience, Halifax, Canada maximal follow up, mean Height/Age Z-score was 0.1±1.2. Twenty patients (29%) reached their final height that was at Background: The diagnosis of inflammatory bowel disease (IBD) least 4 cm below their target height. A total of 2112 height in children, with abdominal pain as a prominent symptom, measures were available. Growth velocity was not influenced is emotionally challenging for children and their families, as